High Potency Active Pharmaceutical Ingredient Market: Rising Incidence of Cancer to Boost the Market

The capital intensive nature of manufacturing activities of high potency active pharmaceutical ingredient have been a major subject of concern for the players in this market. Furthermore, the manufacturing of these drugs need highly skilled labors, which could increase the labor cost hence the cost of the pharmaceutical ingredient. This can act as a restraining factor for growth of the market. In addition, the absence of norms pertaining to environmental, health, and occupational safety while manufacturing and researching potency APIs is threatening the market growth.

Transparency Market Research has estimated that the HPAPI market valued at US$2.64 bn in 2014 and expected to reach US$25.11 bn by 2023, while exhibiting a steady CAGR 8.3% during the forecast period 2015-2023.

Regionally, Asia Pacific is expected to show significant opportunities to the market due to soaring contract manufacturing activities in the region. Within this region, Japan contributes the leading share. However, due to supportive foreign exchange policies, well-equipped manufacturing plants, and low labor costs, China is expected to surpass Japan’s total revenue in the forthcoming years.

Nevertheless, the increasing incidence of cancer are expected to help the market sustain its growth. The escalating occurrence of cancer have augmented the research and development activities in healthcare sectors of various regions such Asia Pacific and North America. This has resulted in the increased demand for effective anticancer drugs, assisting growth of the high potency active pharmaceutical ingredient market.

Request and Download Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=748

The vendor landscape of the global high potency active pharmaceutical ingredient (HPAPI) market is highly fragmented due to presence of a large number of players. Some of the prominent players in this market are WuXi AppTec, Pfizer, Inc., Novartis AG, Lonza Group, Novasep, Dr. Reddy’s Laboratories Ltd., Cambrex Corporation, and Sigma-Aldrich Corporation. Transparency Market Research has estimated that the individual revenue share of these players range between 3% and 4% of the overall market. These players are focusing on cost containment to sustain their profit margins. Furthermore, various companies in this market are involving in strategic partnerships to remain significant occupant and gain the first-mover advantage in the market.

Be the first to comment

Leave a Reply

Your email address will not be published.